Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2940)	5/14/2020 12:33:23 AM
From: Felix B	Read Replies (1) \| Respond to of 3557

Fairly certain most executive suite have pre determined dates when they are selling stock that is defined far in advanced from earning dates. I think the timing here is coincidental but what do I know

To: Miljenko Zuanic who wrote (2940)	5/14/2020 8:26:30 AM
From: Biotechwantabe	Read Replies (1) \| Respond to of 3557

Nice pay day for Len. Approximately >150m. Still owns >250m. Probably has a ton more option coming. George’s sell at 420 look silly now. But I guess they need to diversify. If nAbs fail then recovery will take longer or worse. Hedge is smart. Cost to the economy will be T$. I also bought VIR just in case REGN fails. Looking forward Animal data. Why is it not ready to publish? Phase 1 start

To: Miljenko Zuanic who wrote (2940)	5/14/2020 9:02:02 AM
From: Biotechwantabe	Read Replies (1) \| Respond to of 3557

I hope they are spending lots to create manufacturing capacity for nAbs. And lining up partners if they can’t build enough on own. Down side is they have to much capacity for a few years and $ spent. But that would be minor in comparison to benefit if successful.